Atika Capital Management’s CareDx CDNA Stock Holding History

Atika Capital Management’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-73	Closed	-$66.7K	–	88
2023 Q1	$66.7K	Buy	+73	New	+$934	0.01%	77

Other funds holding CDNA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Atika Capital Management's CDNA Position: Q3 2021 in Review

Atika Capital Management sold out of CareDx (CDNA) in Q3 2021, closing a stake of 124,000 shares — an estimated $11.3M sold.

Atika Capital Management first reported a position in CDNA in Q2 2021 and held it in 1 quarter. The position peaked at $11.3M in Q2 2021. 260 funds tracked by Wall St. Rank hold CDNA as of Q3 2021.

Atika Capital Management reported no remaining CareDx position as of Q3 2021 after selling out during the quarter.
Atika Capital Management sold 124,000 CareDx shares in Q3 2021, an estimated $11.3M.
Atika Capital Management first reported a position in CareDx in Q2 2021 and held it in 1 quarter.
Atika Capital Management's CareDx position peaked at $11.3M in Q2 2021.
260 funds tracked by Wall St. Rank held CareDx as of Q3 2021.

Based on Atika Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.